Pharmacokinetics and pharmacodynamics of pantoprazole in clinically normal neonatal foals.

Summary

# Pantoprazole in Neonatal Foals: Pharmacokinetic and Pharmacodynamic Profile Proton pump inhibitors represent the gold standard for managing acid-related ulceration across species, yet equine practitioners in the USA have historically relied on a single oral omeprazole formulation—a significant limitation when treating neonatal foals unable to tolerate oral dosing. Ryan and colleagues investigated the pharmacokinetics and pharmacodynamics of intravenous pantoprazole in healthy neonatal foals to establish whether this alternative PPI could offer a viable parenteral option for acid suppression. The study characterised drug absorption, distribution, metabolism, and the resulting suppression of gastric acid production following IV administration in foals, with measurements tracking plasma concentrations and intragastric pH changes over defined time periods. By providing detailed pharmacokinetic parameters and demonstrating effective acid suppression via the IV route, this work established the scientific foundation for using pantoprazole as a practical alternative when oral delivery is contraindicated—particularly valuable in colicky neonates, those with oesophageal dysfunction, or foals recovering from critical illness. These findings have important implications for managing gastric ulceration risk in vulnerable foal populations where medication compliance and delivery method directly influence treatment success.

Read the full abstract on PubMed

Key Findings

• •Proton pump inhibitors are a mainstay treatment for acid-related ulceration in horses, with omeprazole currently being the only FDA-approved oral preparation in the USA
• •Intravenous administration of pantoprazole would provide a therapeutic alternative for foals unable to receive oral medication

Conditions Studied